卡马西平与加巴喷丁治疗三叉神经痛的疗效及安全性比较

Comparison of the Efficacy and Safety of Carbamazepine and Gabapentin in the Treatment of Trigeminal Neuralgia

目的:探讨卡马西平与加巴喷丁治疗三叉神经痛的疗效及安全性。方法:选取2014年2月至2015年12月收治的88例三叉神经痛患者为研究对象,以随机数字表法分为2组,A组44例应用加巴喷丁治疗,B组44例应用卡马西平治疗,对2组患者治疗后疼痛程度、安全性进行观察对比。结果:治疗后,A组总有效率达88.64%,显著高于B组(68.18%)(P<0.05);治疗前2组患者VAS评分差异无统计学意义(P>0.05),治疗后均有下降,A组在治疗后1周、2周、4周时间点的VAS评分均低于B组,2组差异有统计学意义(P<0.05);A组治疗后不良反应发生率为15.91%,显著低于B组(40.91%)(P<0.05)。结论:卡马西平与加巴喷丁治疗三叉神经痛均有一定疗效,但加巴喷丁疗效更为显著,且安全性更高,可作为首选治疗方案。

Objective： To investigate the efficacy and safety of Gabapentin and Carbamazepine in the treatment of trigeminal neuralgia. Methods： A total of 88 cases of patients with trigeminal neuralgia from Feb 2014 to Dec 2015 were selected as subjects and were divided into 2 groups by random number table method, 44 cases in each group. One group was treated with Gabapentin （group A）, and the other group was treated with Carbamzepine （group B） . Pain relief and safety were comparatively analyzed between the two groups. Results： After treatment, the total effective rate in group A was 88.64%, which was significantly higher than that in group B （68.18%） （P〈0.05） . There was no significant difference in VAS scores before treatment （P〉O.05）, but the VAS scores gradually decreased after treatment. The VAS scores in group A at 1, 2 and 4 weeks after treatment were significant lower than those in group B respectively （P〈0.05） . The incidence rate of adverse reactions in group A was 15.19%, which was lower than that in group B （40.91%）, the difference was statistically significant （P〈0.05） . Conclusion： Both of Gabapentin and Carbamazepine are effective and safe in the treatment of trigeminal neuralgia, but Gabapentin has better efficacy and safety than Carbamazepine.